Kadono, Y., S. Kawaguchi, T. Nohara, K. Shigehara, K. Izumi, T. Kamijima, C. Seto, A. Takano, S. Yotsuyanagi, R. Nakagawa, T. Miyagi, S. Aoyama, H. Asahi, R. Fukuda, and A. Mizokami. “Favorable Response of Pembrolizumab As Second-Line Therapy for Advanced Urothelial Carcinoma With Only Small Lesions to Not Be Considered Measurable by RECIST”. Urology Journal, Vol. 19, no. 03, Dec. 2021, pp. 202-8, doi:10.22037/uj.v18i.6652.